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Upstream factor-2The technique of in vivo electroporation was adapted to investigate the promoter elements and transcription
factors mediating the rapid induction of hepatic LDL receptor expression in response to thyroid hormone. Di-
rect comparisons between wild type and mutant promoter constructs were made within the same animal. It
was demonstrated that both TREs at bp −612 and −156 were required for the L-triiodothyronine (T3) re-
sponse. ChIP analysis showed that binding of TRβ1 to the −612 and −156 TREs was markedly stimulated
by T3 in vivo. Introduction of siRNAs against TRβ1/RXRα with LDL receptor promoter-luciferase construct
by in vivo electroporation demonstrated that these transcription factors play the major physiological role
in the activation of hepatic LDL receptor transcription. The ﬁndings agree with those made by transfecting
H4IIE cells in vitro thus validating this technique for in vivo studies of mechanisms of transcriptional regula-
tion. The ﬁndings reported herein also indicated, for the ﬁrst time, that PPARα and USF-2 were required for
maximum transcriptional activation of the LDL receptor in response to T3 treatment.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
1.1. Thyroid hormone and cholesterol
Thyroid hormone acts rapidly to stimulate transcription of the he-
patic low density lipoprotein (LDL) receptor several fold (Ness and
Lopez, 1995). This action is critical to the serum cholesterol-lowering ef-
fect of this hormone (Ness, 1991). In fact, hypothyroidism has been as-
sociated with elevated levels of LDL cholesterol (Illingworth et al.,hyroid response elements; T3,
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tical Sciences, College of Arts
echnology Enterprise (BRITE),
reet, Durham, NC 27707, USA.
-NC-ND license. 1981), and treatmentwith thyroid hormone effectively lowers LDL cho-
lesterol (Aviram et al., 1982). This has led to the development of
thyromimetics as possible anti-cholesterol drugs (Underwood et al.,
1986; Leeson et al., 1989; Ness et al., 1998; Morkin et al., 2004;
Valadares et al., 2009).
1.2. Use of rat hepatoma cells
In a prior investigation, rat hepatoma H4IIE cells in culture were
used to identify two thyroid response elements (TREs) in the rat
LDL receptor promoter (Lopez et al., 2007). The elements identi-
ﬁed were: an upstream TRE at bp−612 and a two half-site TRE at bp
−156, relative to the transcription start site (Lopez et al., 2007). Bind-
ing of thyroid hormone receptor β1 (TRβ1) to both elements was dem-
onstratedwith binding to the−612 element beingmuch stronger than
to the−156 element (Lopez et al., 2007).Mutation of theweaker−156
element did not signiﬁcantly affect induction by L-triiodothyronine (T3)
(Lopez et al., 2007). However, mutation of both elements was required
to completely abrogate T3 induction of the LDL receptor promoter activ-
ity in the H4IIE cells (Lopez et al., 2007).
1.3. In vivo electroporation
The technique of efﬁciently transfecting rat liver cells in vivo
using electroporation, for introduction of plasmid constructs has
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1998). In a study using a β-galactosidase construct, it was demon-
strated that 30% to 40% of liver cells expressed the β-galactosidase
genetic marker (Heller et al., 1996). Thus, we employed this in vivo
electroporation technique to study the elements and transcription
factors mediating induction of hepatic LDL receptor transcription
by T3 in a live animal. Rat LDL receptor luciferase constructs, as
well as siRNAs to knockdown speciﬁc transcription factors, were di-
rectly introduced into livers of live rats by in vivo electroporation.
2. Results
2.1. Localizing in vivo transfected promoter constructs
Using our 5 mmhexagonal array electrode, we introduced rat LDL
receptor promoter-luciferase reporter gene constructs and/or
siRNAs, in duplicate, into each of three liver lobes in the same animal.
This allows for direct comparisons. The area transfected is limited to
that inside the hexagonal array. After 24 hours, the transfected areas
were removed using a 5 mm cork borer. The precise location of the
transfected regions is deﬁned by six light dots due to electrode scar-
ing on the liver surface. Luciferase activity is restricted to the 5 mm
circle as demonstrated in Fig. 1.
2.2. In vivo evaluation of the −612 and −156 TREs
The in vivo contributions of the TREs located at bp−612 and−156,
relative to the transcription start site, to T3 stimulation of LDL receptor
transcription was evaluated by introducing receptor promoter con-
structs into rat livers by in vivo electroporation. The rat wild-type
(WT),−156mutant (−156Mt),−612 mutant (−612Mt), and doubleFig. 1. In vivo imaging of liver sites where promoter luciferase constructs were introduced
using a Xenogen in vivo Imager. Luciferase substrate was injected intraperitoneally prior tomutant (DbMt) LDL receptor promoter constructs were introduced into
separate liver lobes of normal (NR), hypophysectomized (Hx), and
T3-treated hypophysectomized (Hx+T3) rats, for direct compari-
sons within the same animal. As shown in Fig. 2A, the promoter
activity of the WT construct was 39% lower in the Hx than in the
NR rats. Treating with a single dose of T3 (after electroporation)
16 hours before euthanization caused a signiﬁcant (pb0.01) induc-
tion (2.4-fold) in LDL receptor promoter activity as compared to
the activity observed in the Hx animals (Fig. 2A). These changes in
LDL receptor promoter activity directly correlated with changes in
free T3 (fT3) (Fig. 2B) and hepatic LDL receptor mRNA levels
(Fig. 2C). Fig. 3A illustrates the results for the mutation analysis ex-
periment. For this speciﬁc experiment, the Hx rats were treated
with two injections of T3, 72 and 24 hours prior to electroporation,
as indicated under Materials and methods. As shown, the activity of
the WT construct was increased 8.42-fold in response to two doses of
T3, when compared to the LDL receptor promoter activity seen in the
Hx animals (Fig. 3). Mutating the−612 TRE reduced the T3-dependent
stimulation of the LDL receptor promoter about 49% (Fig. 3). Similar-
ly to the results obtained in H4IIE cells (Lopez et al., 2007), mutating
the −156 TRE had no signiﬁcant effect on the T3 dependent activa-
tion of the LDL receptor promoter (data not shown). When both
TREs were mutated, the stimulation by T3 was reduced by 76%
(Fig. 3).2.3. In vivo analysis of transcription factor binding to the LDL receptor
promoter
To investigate the effect of T3 treatment on the binding of different
transcription factors to the TREs in vivo, ChIP assays were performed
as described under Materials and methods. As shown in Fig. 4, T3into a normal (NR) rat. Imaging was performed 24 hours after in vivo electroporation
imaging. The regions of interest (ROI) are circled.
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Fig. 3. In vivo contributions of the −612 and −156 TREs to the T3-dependent activa-
tion of the LDLR promoter. For this experiment, 10 μg of the WT, −612Mt, and DbMt
LDLR promoter constructs were electroporated into the livers of Hx and Hx+T3 rats.
Two doses of T3 were given 72 and 24 hours before electroporation as described
under Materials and methods. Lysate preparation and luciferase assays were carried
out. The data are presented as mean LDLR promoter activity±SEM for at least four
electroporation sites per each treatment condition. p Values were obtained by compar-
ing to the WT construct.
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Fig. 4. In vivo binding of transcriptional factors to the LDL receptor promoter. ChIP
assay followed by real-time PCR analysis were performed on liver samples obtained
from Hx and Hx+T3 rats. Negative (IgG) and positive (RNA Pol II) control antibodies
were used. PCR data were normalized to input DNA and presented as mean binding en-
hancement by T3±SEM, where the binding to chromatin from livers of Hx+T3 rats
was expressed relative to the binding to chromatin from livers of Hx rats. All the differ-
ences shown were found to be statistically signiﬁcant (pb0.05), relative to the total
input DNA. Samples from at least four animals were considered for each treatment
condition.
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Fig. 2. Effects of T3 on the expression of the LDL receptor gene in rat livers. A. In vivo
reporter gene studies using electroporation. For this experiment, 40 μg of the WT
LDL receptor (LDLR) promoter construct were injected at different sites into the livers
of NR and hypophysectomized (Hx) rats. Some of the Hx rats received 1 dose of T3
16 hours before euthanization (Hx+T3). Preparation of liver lysates and measurement
of luciferase activity were carried out as described under Materials and methods. The
data are presented as mean LDLR promoter activity±SEM for six electroporation
sites for at least two animals. The p value was obtained by comparing the Hx and
Hx+T3 conditions. B. Levels of fT3 in serum samples obtained from the same animals
used in (A.) were determined using ELISA. The data are presented in term of pg/dl. p
Values were obtained by comparing NR versus Hx and Hx versus Hx+T3, respectively.
C. Effect of T3 on hepatic LDLR mRNA levels. Total RNA samples prepared from the same
rats employed in (A.) were analyzed by real-time RT-PCR using LDLR speciﬁc primers.
The data are represented as mean relative LDLR mRNA levels±SEMwhere the value of
receptor mRNA for the normal sample was set to 1.0. The p value was obtained by com-
paring the Hx and Hx+T3 conditions.
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sites. The degree of binding enhancement was about 3.65- and
3.0-fold for the −612 and −156 motifs, respectively, similar to the
binding enhancement seen with the positive control, RNA Pol II
(Fig. 4). Binding of RXRα, by itself, to the−612 and−156 elements,
was minimal (data not shown). However, T3 treatment enhanced the
binding of TRβ1 together with RXRα to about 2-fold for both TRE
sites (Fig. 4). Interestingly, signiﬁcant binding enhancements were
also observed for PPARα and USF-2, two transcriptional factors also
known to bind to these promoter elements (Adams et al., 2010;
Boone et al., 2009; Jackson-Hayes et al., 2003).2.4. In vivo siRNA studies
To evaluate the relative involvement of endogenous TRβ1,
PPARα, and USF-2 in mediating transcriptional activation of the he-
patic LDL receptor gene by T3, siRNAs to knockdown these transcrip-
tional factors were utilized. The siRNAs were introduced by in vivo
electroporation together with the WT LDL receptor promoter con-
struct into euthyroid rats. The LDL receptor promoter activity
obtained in the presence of the siRNAs was directly compared with
the promoter activity seen in the presence of saline. As shown in
Fig. 5A, the receptor promoter activity was reduced to about 25% of
control in the presence of siRNAs against TRβ1. LDL receptor mRNA
levels were reduced to about 35% of control by the same siRNAs
(Fig. 5B). Knockdown of PPARα and USF-2 using siRNAs signiﬁcantly
reduced LDL receptor promoter activity to about 35% of control
(Fig. 5A), while LDL receptor mRNA levels were reduced to about
50% of control (Fig. 5B).
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Fig. 5. Effects of in vivo siRNA knockdown of transcriptional factors on LDL receptor
gene expression. Studies were performed in NR rats. Six sites, two in each liver lobe,
were injected with the WT LDLR promoter construct and the indicated siRNAs or saline
(negative control), followed by electroporation of the injection site. A. Liver punches
were excised 24 hours later for lysate preparation followed by luciferase assays.
B. Liver samples adjacent to the electroporation sites were used in the preparation of
RNA samples that were analyzed using real-time PCR. In both panels, the data are
reported as mean±SEM for at least eight animals per treatment condition. p Values
were obtained by comparing to the activity of the WT construct in the presence of
saline.
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Fig. 6. In vitro conﬁrmation of the role of PPARα and USF-2 on the T3-dependent acti-
vation of the LDL receptor gene. Studies were performed in H4IIE cells grown in a thy-
roid hormone deﬁcient medium. A. Promoter analysis experiment. Cells were
co-transfected with the WT LDL receptor promoter construct, the TRβ1-pCMVS4 and
RXRα-pRcRSV expression plasmids, the Renilla plasmid, and the indicated siRNAs
using Fugene 6 transfection reagent. Lysing of the cells was performed 48 hours after
transfections. Some cells were treated with T3 (1 μM) and 9-cis retinoic acid
(RA; 1 μM) for 16 hours prior to lysing. Luciferase assays were carried out as described
in Materials and methods. B. Analysis of mRNA levels. Cells were transfected with con-
trol siRNAs or with siRNAs for either PPARα or USF-2 as described above. Treatment
with T3 and RA was carried out as described in A. Cells were used in the preparation
of RNA 24 hours after transfection. RNA samples were analyzed using real-time PCR.
In both panels, the data are presented as mean±SEM for three samples per treatment
condition. p Values for the samples transfected with the control siRNA and treated with
T3/RA were obtained by comparing to the control siRNA samples no treated with the
hormones. All the other p values were obtained by comparing to the control siRNA
sample treated with T3/RA.
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To conﬁrm the involvement of PPARα andUSF-2 in the T3-dependent
transcriptional activation of the hepatic LDL receptor gene, knockdown
studies using siRNAs against these two transcription factorswere carried
out inH4IIE cells. The LDL receptor promoter activity and receptormRNA
levels obtained in the presence of the siRNAs against PPARα and USF-2
were directly compared with the results obtained in the presence of a
negative control siRNA. In the presence of T3/9-cis retinoic acid (RA),
the receptor promoter activity was reduced to about 30% of control
when siRNAs against PPARα and USF-2 where introduced (Fig. 6A). In
agreement, LDL receptormRNA levelswere reduced to about 50% of con-
trol by the same siRNAs (Fig. 6B).
3. Discussion
3.1. Direct activation
Thepresent study demonstrated that T3 activates transcription of the
hepatic LDL receptor in vivo through TREs located at −612 and −156,
with the −612 element being the major element. These results are in
agreementwith previous in vitroﬁndingsmade using rat liver hepatoma
cells (Lopez et al., 2007). T3 activation of LDL receptor transcription
through these sites via the TRβ1, the major thyroid hormone receptor
in liver (Angelin and Rudling, 2010), explains the rapid (within
1 hour) activation of receptor transcription previously reported (Nessand Lopez, 1995; Ness and Zhao, 1994). T3 acts directly rather than via
the sterol response element binding protein (SREBP) pathway to acti-
vate hepatic LDL receptor transcription (Lopez et al., 2007; Costet,
2010), since it was demonstrated that T3 failed to restore SREBP-2 levels
within the 2-hour time period when transcription of the LDL receptor is
fully activated (Lopez et al., 2007).
3.2. Requirement for both TREs
Previously, binding of TRβ1 to the −612 and −156 sites of LDL
receptor promoter was demonstrated in vitro using electrophoretic
mobility shift assays (EMSA) (Lopez et al., 2007). In vitro, the binding
of TRβ1 to the−612 site was found to be stronger than the binding
to−156 (Lopez et al., 2007). Herein, ChIP assays demonstrated that
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a similar extent. Interestingly, the binding of TRβ1 by itself to the LDL
receptor TREs was shown to be 1.83-fold higher than the binding of
TRβ1/RXRα heterodimers.
TRβ1 is a type II nuclear receptor, which in the absence of T3, usu-
ally binds to TREs in the promoter of target genes as heterodimers
with RXRα (Harvey and Williams, 2002; Yen, 2001). Under these
conditions, the TRβ1/RXRα complex interacts with corepressor pro-
teins (i.e., NcoR2, TRAC-1, or SMRTe), which assist in repressing tran-
scription of a target gene (Harvey and Williams, 2002; Yen, 2001).
When T3 is present, the corepressor is released as a result of a confor-
mational change in TRβ1 (Harvey and Williams, 2002; Yen, 2001).
This leads to recruitment of coactivator proteins, such as TRAP
(Harvey and Williams, 2002; Yen, 2001). The complex formed be-
tween the TRE motif, TRβ1/RXRα, and the coactivator, recruits RNA
polymerase resulting in an increase in transcription of the target
gene (Harvey and Williams, 2002; Yen, 2001). Thus, our ﬁnding
that, in the case of the LDL receptor, T3 enhances the binding of
TRβ1, possibly in the form of homodimers, and to a lesser extent, of
TRβ1/RXRα heterodimers, to the receptor promoter, represents a
novel in vivo regulatory mechanism of transcriptional regulation by
thyroid hormone. In fact, the binding of T3 receptors in the form of
monomers and/or homodimers has been reported only in in vitro as-
says (Miyamoto et al., 1993). Additional studies are required to iden-
tify corepressor and/or coactivator proteins associated with the
transcriptional regulation of the LDL receptor gene in the absence
and presence of T3, respectively.
3.3. Possible role of PPARα and USF-2
In vivo and in vitro knockdown studies using siRNAs against PPARα
and USF-2 conﬁrmed that these two transcription factors are required
for maximum T3-dependent activation of the LDL receptor promoter.
PPARα is a nuclear receptor that like the T3 receptor, it has the ability
to form heterodimers with RXRα, bind to the half-site AGGTCA, and
activate transcription in response to its ligand (fatty acids) (Forman
et al., 1997; Stael et al., 1998). It is possible that in the case of the
LDL receptor, PPARα competes with TRβ1/RXRα for the same binding
sites, and since T3 can enhance fatty acid synthesis in the liver
(Blennemann et al., 1992), the excess of fatty acids could promote
PPARα binding to the LDL receptor gene. In fact, activation of PPARα
has been reported to induce the expression of the hepatic LDL receptor
both in vitro and in vivo. (Huang et al., 2008). Furthermore, ﬁbrates such
as fenoﬁbrate, which are synthetic ligands for PPARα, activate LDL re-
ceptor transcription (Huang et al., 2008). It will be interesting to inves-
tigate in future studies whether PPARα/TRβ1/RXRα could form trimers
on the LDL receptor TREs.
USF-2, on the other side, binds to E-box motifs (Corre and
Galibert, 2005), and in agreement with this, several E-boxes have
been identiﬁed around the LDL receptor TREs, especially the −156
motif (Lopez and Ness, 2006). Interestingly, USF-2 has been implicated
in the T3-dependent regulation of genes such as HMG-CoA reductase
and carnitine palmitoyltransferase-I (CPT-I). In the case of the CPT-1
gene, USF-2 is able to directly interact with TR to regulate transcription.
Thus, it could be possible that USF-2, PPARα, and TRβ1/RXRα are able to
cooperate in vivo to control the transcription of the LDL receptor. There
are no previous reports linkingUSF-2 to the transcriptional activation of
the LDL receptor gene.
4. Conclusion
The ﬁndings reported herein extend the previous observations
made in rat hepatoma cells to the whole animal. They indicated that
both the −612 and −156 TREs are required for in vivo activation of
hepatic LDL receptor transcription by thyroid hormone. These studies
also conﬁrmed that TRβ/RXRα are the primary transcription factorsinvolved in this process, but showed, for the ﬁrst time, that PPARα
and USF-2 are required for maximum activation of the LDL receptor
promoter in the presence of T3.
5. Materials and methods
5.1. Experimental animals
NR and Hx male Sprague–Dawley rats, weighing 125 to 150 g,
were purchased from Harlan (Indianapolis, IN). NR rats received
Tekland rat chow and water ad libitum. Hx rats received Tekland Io-
dine Deﬁcient chow and water ad libitum. Both sets of rats were
housed in a reverse-cycle light-controlled room with a 12-hour
light/dark period. In some experiments, Hx rats used in electropora-
tion received a single injection of 0.1 mg/kg T3 16 hours prior to
euthanization. In other experiments, Hx rats received an injection
of 1.0 mg/kg T3 72 hours prior to electroporation and an additional
injection of 0.25 mg/kg T3 24 hours prior to electroporation. These
rats were euthanized 24 hours following electroporation, at the
mid-dark period (Boone et al., 2009). The animals were cared for
according to the NIH guidelines set forth in the “Guide for the Care
and Use of Laboratory Animals”. All procedures were conducted
according to protocol 3571 approved by the University of South
Florida Institutional Animal Care and Use Committee.
5.2. Plasmid construction
The rat WT, −156Mt, −612Mt, and DbMt LDL promoter-
luciferase reporter gene constructs were prepared as previously de-
scribed (Lopez et al., 2007; Lopez and Ness, 2006). All clones were
conﬁrmed by restriction analysis followed by DNA sequencing at
Genewiz, Inc. (South Plainﬁeld, NJ).
5.3. In vivo electroporation
Ten to forty μg of the indicated LDL receptor promoter constructs
were directly introduced into the livers of rats by electroporation as
recently described (Lagor et al., 2007). pHRL-CMV Renilla vector
(Promega, Madison, WI) was co-electroporated at a 1:2000 dilution
to control for electroporation efﬁciency. The total volume of injected
DNA was 50 μL as previously described (Boone et al., 2009). Two
5 mm electroporation sites in each of three liver lobes per rat were
used. The area transfected is restricted to that inside the 5 mm circle
as evidenced by imaging of live rats (Fig. 1).
5.4. Luciferase assays
The livers of electroporated animals were harvested 24 hours fol-
lowing electroporation. Once removed, the electroporated regions of
the liver were extracted using a 5 mm cork-borer. A circle of six
small dots deﬁned the transfection sites. Approximately 100 mg of
liver was placed in 2 mL of 1× Passive Lysis Buffer (Promega Corp.,
Madison, WI) and homogenized using a Polytron tissue disrupter.
The lysate was centrifuged at 16,000 ×g for 5 minutes and the super-
natant assayed for luciferase activity using the Dual Luciferase Assay
Kit from Promega. Luciferase activity was calculated as the average
ratio of ﬁreﬂy (reporter) to renilla luciferase (Boone et al., 2009).
5.5. Thyroid hormone assay
Blood was collected from animals at time of euthanasia and
centrifuged at 16,000 ×g for 5 min. Supernatant was collected and
used for determination of T3 levels using the fT3 ELISA from
Calbiotech (Spring Valley, CA) (Lopez et al., 2007; Boone et al., 2009).
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Total RNA was isolated using TRI Reagent (Molecular Research
Center, Cincinnati, OH) either from liver samples distant from
electroporated sites (to determine basal mRNA levels) or from adja-
cent sites electroporated with siRNAs (to measure the effects of
those siRNAs on endogenous LDL receptor mRNA levels). The RNA
samples were DNAse treated using the TURBO DNA-Free Kit
(Ambion, Austin, TX) and converted to cDNA using the Reverse Tran-
scription System (Promega) as previously described (Lopez et al.,
2007). Primer sequences for the rat LDL receptor and the 18s rRNA
have been previously listed (Lopez et al., 2007). The parameters for
the PCR reactions were denaturation at 95 °C for 5 minutes, followed
by 40 cycles of 95 °C for 15 seconds and annealing and extension at
61 °C for 1 minute. The melt curve started at 55 °C and increased by
0.5 °C each 10 seconds until it reached 95°. All samples were run in
duplicate on a Bio-Rad Chromo4 DNA Engine thermal cycler using
SYBR green chemistry (Lagor et al., 2007). The data were analyzed
by the Comparative CT method as previously described (Lagor et
al., 2007).
5.7. Chromatin immunoprecipitation (ChIP) assay
Chromatin was prepared and immunoprecipitated using the
Pierce Agarose ChIP Kit (Pierce Corp, Rockford, IL). All named buffers
were included in the kit. Liver samples, 100 mg each, were taken
from NR, Hx, and Hx+T3. The tissue was minced and ﬁxed in
10 mL of 1% formaldehyde Fixation Solution for 10 minutes at
room temperature. One mL of Glycine Solution was added to each
tube. After rotating for 5 minutes, samples were centrifuged for
5 minutes at 720 ×g. The pellets were resuspended in 10 mL 1×
PBS (Wash 1) and centrifuged at 720 ×g for 5 min. The supernatant
was aspirated and Wash 1 was repeated. The cell pellets were
resuspended in 1 ml ice-cold 1× PBS supplemented with 10 μL Halt
Cocktail (containing protease inhibitors) and incubated on ice for
30 minutes. The cells were homogenized in a Dounce homogenizer
using 10 strokes on ice to release the nuclei, transferred to a 1.5 mL
tube and centrifuged at 3000 ×g for 5 minutes at 4 °C. The nuclei
were resuspended in 1 mL of Lysis Buffer 1, vortexed for 15 seconds,
and incubated on ice for 10 minutes. The tubes were centrifuged at
9000 ×g for 3 minutes and the supernatant was discarded. The nu-
clei were resuspended in 1 mL of MNase Digestion Buffer Working
Solution and 2.5 μL Micrococcal Nuclease (based on optimization re-
sults), vortexed and incubated in a 37 ° C water bath for 15 minutes
(mixed by inversion every 5 minutes). Tenmicroliters of MNase Stop
Solution was added to each tube, vortexed, and incubated on ice for
5 minutes. Each tube was centrifuged for 5 minutes to recover nuclei
and the supernatant was discarded. The nuclei was resuspended in
50 μL of Lysis Buffer 2 and incubated on ice for 15 minutes, vortexing
for 15 seconds every 5 minutes. Each tube was centrifuged at
9000 ×g for 5 minutes and the supernatant (containing digested
chromatin) was transferred to a new 1.5 mL tube. Chromatin size
was checked by agarose electrophoresis to ensure an average size
between 200 and 500 bp. Forty-ﬁve microliters of chromatin, 5 μg
of antibody, and 20 μL of Agarose resin were used per each immuno-
precipitation (IP) reaction. The antibodies used for the IP reactions
were: USF-2 (SCBT, sc-861x), RXRα (SCBT, sc-553x), TRβ1 (SCBT,
sc-33312x), and PPARα (SCBT, sc-9000x), all from Santa Cruz Bio-
technology (Santa Cruz, CA). The negative (IgG) and positive (RNA
Pol II) control antibodies were provided part of the Pierce Agarose
ChIP Kit. The reactions containing antibodies were rotated at 4 °C
for at least 15 hours. Final DNA samples were analyzed in triplicates
by real-time PCR as described under real-time PCR method above
with the omission of a melt curve. The primers used to the PCR reac-
tions were: 5′-CTCTGAGTGCTATTTATGGT-3′ and 5′-CGGAGCTCCCA
ACTCGTGTG-3′ for −612 and 5′-AACCTCGTCCCTAGGGCTGA-3′ and5′-ACAGGATCACGGGTCCCACG-3′ for −156. The relative level of
transcription factor binding was quantiﬁed by correcting for the
amount of input DNA and negative control antibody DNA (back-
ground). Relative induction of binding was calculated as the ratio
of relative binding of the factor in the Hx+T3 chromatin preparation
to the relative binding of the factor in the Hx chromatin preparation.
5.8. siRNA knockdown study
Ten μg each of USF-2 siRNA (SABiosciences cat# SIR449799ABCD;
Valencia, CA), PPARα siRNA (Dharmacon cat# LQ-080000-01-0010;
Lafayette, CO), and TRβ1 siRNA (Dharmacon cat# LQ-097456-
01-0010)were co-electroporated with 10 μg ofWT LDL receptor pro-
moter construct in a ﬁnal volume of 50 μL using 6 sites per animal.
Saline was used as the negative control for the siRNA samples. The
electroporated sites were removed 24 hours later using a 5 mm
cork-borer. Lysates were prepared from electroporated sites. Lucifer-
ase assays were performed as described above. Liver samples adja-
cent to the electroporation sites were used in the preparation of
RNA samples that were analyzed using real-time PCR to measure
knockdown of endogenous LDL receptor mRNA (Boone et al., 2009).
5.9. In vitro studies
For the promoter analysis experiments, cells were plated in
12-well plates at the density of 1×105 cells per well and incubated
for 24 hours at 37 °C, 5% CO2, in low glucose-DMEM medium
supplemented with 5% (v/v) thyroid hormone depleted serum
(THDS) and antibiotics. The THDS was prepared using Dowex resin
as previously described (Samuels et al., 1979). Cells were co-
transfected with the WT LDL receptor promoter construct and the
TRβ1-pCMVS4 and RXRα-pRcRSV expression plasmids, 1 μg of each
recombinant vector per well, using Fugene 6 transfection reagent,
as previously described (Lopez et al., 2007; Lopez and Ness, 2006).
Wells receiving siRNAs for either PPARα or USF-2 were also
co-transfected with 1 μg total per well, of the indicated siRNAs
(0.25 μg each of the four siRNAs provided for each transcriptional
factor). Control wells were co-transfected with 1 μg per well of the
universal negative control (non-targeting) siRNAs prepared by Inte-
grated DNA Technologies (Coralville, IA). It has been shown in pilot
studies that this negative control does not affect the expression of
the LDL receptor gene (data not shown). Co-transfection of a Renilla
plasmid (0.5 μg per well) under the control of the simian virus 40
early enhancer/promoter region was used to correct for differences
in transfection efﬁciencies. After transfection, the cells were allowed
to incubate for 48 hours at 37 °C, 5% CO2. Sixteen hours prior to the
end of the incubation period, some wells were treated with T3
(1 μM) and 9-cis retinoic acid (RA; 1 μM). Lysate preparation was
carried out as previously described [promoter and T3 paper]. Fireﬂy
and Renilla luciferase activities were measured using the Dual-Glo
Luciferase Assay Kit from Promega and a SpectraMax M5 microplate
reader (Molecular Devices, LLC; Sunnyvale, CA). Luciferase activity
was calculated as the average ratio of ﬁreﬂy to renilla luciferase as
described above (Boone et al., 2009).
For the mRNA analysis experiments, cells were plated in 6-well
plates at the density of 8×105 cells per well and incubated for
24 hours at 37 °C, 5% CO2, in low glucose-DMEM medium sup-
plemented with 5% (v/v) THDS and antibiotics. Cells receiving
siRNAs for either PPARα or USF-2 were transfected with 3 μg total
per well of the indicated siRNAs (0.75 μg each of the four siRNAs pro-
vided for each transcriptional factor) using Fugene 6 transfection re-
agent as described above. Control wells were co-transfected with
3 μg per well of the universal negative control. After transfection,
the cells were allowed to incubate for 24 hours at 37 °C, 5% CO2. Six-
teen hours prior to the end of the incubation period, somewells were
treatedwith T3 (1 μM) and RA (1 μM). RNA isolation and preparation
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2007). Real-time PCR reactions were performed using 100 ng of
ssDNA, the LDL receptor and 18s rRNA speciﬁc primers described
above, the Applied Biosystems SYBR green PCR Master Mix, and the
AB real-time PCR system. The parameters for the PCRs were: dena-
turation at 95 °C for 10 minutes, followed by 45 cycles of denatur-
ation at 95 °C for 30 seconds, annealing at 60 °C for 15 seconds,
and extension at 72 °C for 30 seconds. Once again, quantitation of
the results was performed using the Comparative CT method.
5.10. Statistical analysis
For the in vivo studies, signiﬁcant differences were determined
using Excel's t-test: Two-Sample Assuming Unequal Variances and
conﬁrmed using the nonparametric Wilcoxon matched-pairs signed
rank test. For the in vitro studies, all the experiments were performed
in triplicates. Data from the individual parameters were compared by
analysis of variance (ANOVA) followed by Student–Newman–Keuls
multiple comparison test when applicable. A pb0.05 was considered
signiﬁcant for all tests.
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